Navigation Links
Endexx closes Acquisition of Dispense Labs LLC.
Date:8/7/2013

CAVE CREEK, Ariz., Aug. 7, 2013 /PRNewswire/ -- Endexx Corporation OTC: EDXC Endexx is proud to announce the acquisition of Dispense Labs LLC., the innovator and developer of Autospense™ dispense technologies. This acquisition is a core technology in the M3hub™ technology platform.  Autospense™ is a fully secured, pharmaceutical grade dispensing platform. The inventory control, tracking system, supply chain management, and security features provide a multi-point medical marijuana management platform.  From seed to sale, the system fortifies the industry with a reliable and compliant tracking and inventory control system. The software system operates both internally and external to the system and is capable of integrating with multiple operating systems and specialty functions.

Under terms of the acquisition agreement, Endexx has issued ten million shares of restricted stock for the purchase of Dispense Labs LLC., with an additional 5 million shares to be issued upon Dispense Labs achieving specific performance criteria.  Endexx has also assumed two hundred and thirty five thousand dollars of long term debt. There are five machines fully built with sales pending.  Dispense Labs and Endexx has received multiple indications of interest for this technology solution.  Joe DeRobbio will maintain his position as President of Dispense Labs. Mr. DeRobbio stated, "With the completion of the sale to Endexx,  Dispense Labs is excited to enter the next phase of business. We now have the horsepower to aggressively market the machines in those states where it is legal.  Furthermore Dispense Labs is currently consulting with several clients to provide a complete seed to sale solution and management platform for their business."

Todd Davis, CEO of Endexx, stated, " Autospense™ provides the critical infrastructure component needed to help standardize solid operating systems in the management of medical marijuana and cannabis based products in general."  During the due diligence phase, Endexx has identified in excess of sixty thousand unique sites in the United States and Canada where the Autospense™ machine is applicable.  Endexx, in collaboration with Dispense Labs, has fully researched the current market solutions offered and the competition and believes the Autospense™ system is the only total technology solution in the medical marijuana industry.  The Autospense™ solution can easily be integrated with external software and service solutions as well, allowing for other market alliances and business partners to utilize this core technology to support other industry related ancillary services.

About Endexx:

Endexx Corporation is a micro-cap publicly traded company, representing the interest of its shareholders and collaborating with independent software developers, scientists, engineers, and other companies to build businesses that can thrive collectively in the equity markets. Endexx's team recognizes that individually small companies with new technologies have an extremely difficult time sustaining themselves as stand-alone companies. Through our collaborative practices, individual and group skill sets are better utilized to develop technology and grow the business, while centralizing costs and eliminating redundancies.

The Endexx management team and its advisory group each have at minimum 10-50 years of experience in their respective fields. The business professionals associated with the direction of the company all have experience growing businesses, developing and implementing new technologies and running publicly traded corporations.

Endexx Corporation is ultimately structured to provide a platform for entrepreneurs to thrive, offering maximum return on investment through equity ownership in the parent corporation. Each individual is a shareholder and is encouraged and self-driven to be successful and contribute to the overall objective of increasing shareholder value.

About Dispense Labs

Dispense Labs LLC., has spent several years investing in the research, design and development, and beta testing of Autospense™, a one-of-a-kind technologically driven smart system that allows for the automated dispensing of medical marijuana along with precise inventory control, utilizing predictive analytic algorithm and tracking software.

Autospense is a uniquely designed, high-tech automated dispensing system that exceeds industry standards. The software used is specifically designed to properly control transactions and manage inventory. This will significantly improve profitability, accountability, security tracking and customer satisfaction.

Contact Endexx via email to receive corporate news and updates at Endexx@endexx.com  

http://www.otcmarkets.com/stock/EDXC/quotewww.endexx.com, www.autospense.com  

Safe Harbor Statement

This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements regarding potential sales, the success of the company's business, as well as statements that include the word "believe" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Endexx to differ materially from those implied or expressed by such forward-looking statements. This press release speaks as of the date first set forth above, and Endexx assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, timely development of products, inability to deliver products when ordered, inability of potential customer to pay for ordered products, and political and economic risks inherent in international trade.


'/>"/>
SOURCE Endexx Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Endexx identifies core platform for Medical Marijuana Industry
2. Endexx Acquires Medical Marijuana Management Technology
3. Endexx to attend NAMA Spring Expo for Medical Marijuana Technology Solutions
4. Endexx Enters Into Definitive Agreement to Acquire Dispense Labs, LLC
5. Independa Closes Convertible Note Funding at $2.35 Million
6. Stereotaxis Closes $18.5 Million Private Placement Financings
7. Boston Scientific Closes Cameron Health Acquisition
8. C8 MediSensors Closes $19 million Preferred Stock Financing
9. Igenica Closes $33 Million in Series C Funding
10. BONESUPPORT Closes Second Tranche of Funding
11. PTC Therapeutics Closes $30 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Allergy Diagnostics Market: Scope and Methodology ... are used to determine the presence of allergens ... etc. in the samples by determining the presence ... report on global allergy diagnostics market, analyzes the ... report consists of an executive summary that provides ...
(Date:12/8/2016)... Research and Markets has announced the addition of the "Global ... - Forecast to 2025" report to their offering. ... , , ... a CAGR of around 3.2% from 2015 to 2025. Some of ... extracellular microelectrode arrays and intracellular microelectrodes, research in left-to-right shunt detection ...
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... "I had a terrible time trying to get my grandson ... if the nebulizer had a more child-friendly design, then children would be more likely ... patent-pending NEBY to avoid the need to deliver medication via a nebulizer mask. The ...
(Date:12/8/2016)... ... December 08, 2016 , ... The West Virginia Medical ... 2017. The name change aligns the entire company with its existing Quality ... quality. , “We are very proud of the achievements associated with the West ...
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
(Date:12/8/2016)... NY (PRWEB) , ... December 08, 2016 , ... ... is pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods ... in JMIR Medical Informatics . , Results of the comparative usability study ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
Breaking Medicine News(10 mins):